Shi Yu, Zhang Yang, Zhang Lian, Ma Jun-Ling, Zhou Tong, Li Zhe-Xuan, Liu Wei-Dong, Li Wen-Qing, Deng Da-Jun, You Wei-Cheng, Pan Kai-Feng
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Beijing, China.
Linqu Public Health Bureau, Shandong, China.
Front Oncol. 2019 Dec 17;9:1434. doi: 10.3389/fonc.2019.01434. eCollection 2019.
Telomeres have long been found to be involved in cancer development, while little was known about the dynamic changes of telomere length in carcinogenesis process. The present study longitudinally investigated telomere alterations of cell-free DNA (cfDNA) in 86 gastric cancer (GC) subjects recruited through a 16-year prospective cohort with 2-4 serums collected before each GC-diagnosis from baseline and three follow-up time-points (a total of 276 samples). As the control, 86 individual-matched cancer-free subjects were enrolled with 276 serums from the matched calendar year. In the 73 pairs of baseline serums from GC and control subjects, shortened telomeres showed increased subsequent GC risk [odds ratio (OR) = 9.17, 95% CI: 2.72-31.25 for 1 unit shortening]. In each baseline gastric lesion category, higher risks of GC progression were also found with shortened cfDNA telomeres; ORs per 1 unit shortening were 6.99 (95% CI: 1.63-30.30) for mild gastric lesions, 6.06 (95% CI: 1.89-19.61) for intestinal metaplasia and 15.63 (95% CI: 1.91-125.00) for dysplasia. With all measurements from baseline and follow-up time-points, shortened telomeres also showed significant association with GC risk (OR = 7.37, 95% CI: 2.06-26.32 for 1 unit shortening). In temporal trend analysis, shortened telomeres were found in GC subjects compared to corresponding controls more than 3 years ahead of GC-diagnosis (most < 0.05), while no significant difference was found between two groups within 3 years approaching to GC-diagnosis. Our findings suggest that telomere shortening may be associated with gastric carcinogenesis, which supports further etiological study and potential biomarker for risk stratification.
长期以来,人们发现端粒与癌症发展有关,而对于致癌过程中端粒长度的动态变化却知之甚少。本研究对86名胃癌(GC)患者的游离DNA(cfDNA)端粒变化进行了纵向调查,这些患者来自一个为期16年的前瞻性队列,在每次GC诊断前从基线和三个随访时间点收集2 - 4份血清(共276个样本)。作为对照,招募了86名个体匹配的无癌受试者,并从匹配的历年中收集了276份血清。在73对来自GC患者和对照受试者的基线血清中,端粒缩短显示随后发生GC的风险增加[每缩短1个单位的优势比(OR)= 9.17,95%置信区间:2.72 - 31.25]。在每个基线胃部病变类别中,cfDNA端粒缩短也与GC进展的较高风险相关;每缩短1个单位的OR值,轻度胃部病变为6.99(95%置信区间:1.63 - 30.30),肠化生为6.06(95%置信区间:1.89 - 19.61),发育异常为15.63(95%置信区间:1.91 - 125.00)。综合基线和随访时间点的所有测量结果,端粒缩短也与GC风险显著相关(每缩短1个单位的OR = 7.37,95%置信区间:2.06 - 26.32)。在时间趋势分析中,发现GC患者在GC诊断前3年以上的端粒缩短情况与相应对照组相比更为明显(大多数P < 0.05),而在接近GC诊断的3年内两组之间未发现显著差异。我们的研究结果表明,端粒缩短可能与胃癌发生有关,这为进一步的病因学研究和风险分层的潜在生物标志物提供了支持。